Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokKorai 1. fázis

LpD3.5 Intervention Study in Older Adults- LISA-I Trial

A legfontosabb adatok

Ki végzi
University of South Florida
Hol
Tampa (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
Korai 1. fázis
Résztvevők
15 fő, tervezett
Kezdés
2026. márc. 3.
Tervezett befejezés
2026. nov. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • LpD3.5
  • Placebo
A regiszteradat frissítve
2026. augusztus 31.

Ki vehet részt

The trial is looking for adults aged 60 or older with mild cognitive impairment (mild memory and thinking problems). They take LpD3.5 capsules or placebo capsules for 60 days.

Életkor
60 years and older. Study partners must also be 60 years or older.
Nem
All sexes.
A betegség stádiuma
Mild cognitive impairment diagnosed by a doctor, with a Montreal Cognitive Assessment (MoCA) score between 18 and 25.
Korábbi kezelés
No antibiotic use in the past 30 days. No history of fecal microbiota transplantation (transfer of stool bacteria). No cancer treatment in the past 5 years.
Biomarker vagy leletérték
LBP ≥ 30 μg/mL in plasma (a blood marker linked to a leaky gut).
A részvétel fő kizáró okai
  • Brain or gut surgery in the past 5 years that affected thinking
  • Bowel diseases such as inflammatory bowel disease, Crohn's disease, acid reflux or C. difficile infection
  • Cancer or cancer treatment in the past 5 years
  • Nervous system disorders like epilepsy, Parkinson's disease or ALS
  • Pregnancy, being a prisoner, or serious or terminal illness
A regiszter összes feltétele (8)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Age 60 years and above; (ii) physician based clinically diagnosed MCI and the Montreal Cognitive Assessment (MoCA) score between 18 and 25; iii) LBP ≥ 30 μg/mL in plasma, and (iv) willing to sign informed consent, take intervention regimen, follow study team guidelines and donate sam-ples, as instructed by the study team; and (iv) live with a partner or care giver
  • Study partners in this study must meet the following inclusion criteria:
  • Be 60 years or older
  • Willingness to participate in the study and provide consent
  • Ability to have regular contact with the participant(s)
  • Be knowledgeable about the participant's health, memory, and daily activities
  • Communicate effectively in English

Ki nem vehet részt

  • Brain and gut related surgery within the past 5 years that affected cognitive function: This information will be collected during the initial telephonic screening through an eligibility checklist. (ii) diagnosis of inflammatory bowel disease, ulcerative colitis, Crohn's disease, acid reflux, gastroesophageal reflux disease, Clostridium difficile infection, or any other gastrointestinal disease that might significantly change the microbiome, gut permeability, and inflammation: Participants will be asked about these diagnoses during the telephonic screening, and responses will be documented : Participants will be asked about these diagnoses during the telephonic screening, and responses will be documented. (iii) history of fecal microbiota transplantation and small intestinal bacterial growth: These conditions will also be screened via the initial eligibility questionnaire ad-ministered during the pre-screening phone interview. (iv) history of cancer or cancer treatment in past 5 years: Participants will be asked to report any history of cancer or treatment during the tele-phonic screening (v) nausea, vomiting, food poisoning, constipation, or diarrhea and/or antibiotic use in the past 30 days; These symptoms will be captured via a brief symptom checklist completed at the time of recruitment as well as on-site at the initial study visit. (vi) heavy consumption of pro-biotics, yogurt, or other fermented food (>4 servings per day): Questionnaire on probiotic yogurt, or other fermented food will be administered during the initial screening by telephonic talk as well as on-site visit to capture this information.(vii) critical or terminal illnesses; (viii) having neurological disorders like epilepsy, Parkinson's disease and Amyotrophic lateral sclerosis: These conditions will be assessed via direct questioning during the telephonic pre-screening interview (ix) pregnant or prisoner: Pregnancy status will be determined via verbal confirmation during screening and documented in the eligibility checklist. (x) unable to eat the test product according to the regulations; (xi) participating in other clinical trial; (xii) any diagnosis or condition that renders the subject ineligible at the discretion of the PI and/or the study team

Alkalmassági kérdőív

Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.

  • Életkor

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Department of Neurosurgery and Brain and Spine and Faculty of USF Center for Microbiome Re-search, Microbiomes InstituteTampa, Egyesült ÁllamokContact: Hariom Yadav, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This randomized placebo-controlled clinical study, called the LpD3.5 Intervention Study in Older Adults (LISA), aims to evaluate whether a heat-inactivated postbiotic of human origin (LpD3.5) can serve as a non-pharmacological intervention to reduce gut permeability and inflammation in older adults with mild cognitive impairment (MCI). The study will assess the effects of LpD3.5 supplementation on markers associated with gut health, inflammation, microbiome composition, and cognitive function.

A teljes eredeti leírásKevesebb

Participants aged 60 years or older with clinically diagnosed MCI will receive either LpD3.5 capsules or placebo capsules for 60 days, followed by a 30-day follow-up period. Biological samples and clinical assessments will be collected to evaluate changes in gut permeability, inflammatory markers, microbiome characteristics, and cognitive outcomes. The findings from this study may provide insight into the potential role of postbiotics as a dietary intervention to improve gut health and related outcomes in older adults with MCI.

A vizsgálat 2 csoportja

  • LpD3.5 groupMár használt kezelés, összehasonlításként

    This group will receive LpD3.5 (2 capsules per day) for a duration of 60 days with follow-up at 90-day.

    Kezelés: LpD3.5 és Placebo

  • Placebo groupPlacebo, összehasonlításként

    They will receive a bottle of placebo capsules (2 capsules per day) for a duration of 60 days with follow-up at 90 days

    Kezelés: LpD3.5 és Placebo

Következő lépések

Az orvosodnak

Kérdőlap az orvosnak

PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 1 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.

A PDF letöltése

PDF, US Letter, 1–2 oldal. A4 méretben

A vizsgálati csapatnak

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Postbiotics Intervention to Improve Cognitive Function in Older Adults With Mild Cognitive Impairment (Phase 1)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Kérdések a feltételekről
Forrás: NCT07794956: ki vehet részt
A regiszteradat frissítve
2026. augusztus 31.